mounjaro and semaglutide Mounjaro® vs. Ozempic®: What's the

However, as with any medication, its essential to be aware of its side effects, especially when starting a new treatment

In clinical trials of semaglutide 2.4 mg for weight management (STEP 1), approximately 44% of participants experienced nausea, compared to about 16% in placebo groups

This theory is supported by the clinical data showing that tirzepatide produces comparable appetite suppression with less severe gastric emptying delay

The most cited discontinuation data point is real: in the STEP 1 trial extension , one year after stopping semaglutide 2.4 mg, participants regained about two thirds of their prior weight loss, and cardiometabolic improvements drifted back toward baseline

Unlike short-term diet trends or stimulant-driven methods, GLP-1 therapy works with the bodys natural appetite-regulation systems